7:06 AM ET
8-K
Clinical Trial Data
Acumen Pharmaceuticals Clinical Trial Data
Acumen Pharmaceuticals announced that its Phase 2 ALTITUDE-AD clinical trial of sabirnetug for early Alzheimer’s disease failed to meet its primary endpoint of cognitive and functional decline improvement. The trial also failed key secondary endpoints, leading the company to cease development of sabirnetug and implement cash conservation measures while exploring strategic options.
- Term
- 18 months